Vapotherm, which provides noninvasive breathing aids to treat respiratory distress, announced terms for its IPO on Monday.
The Exeter, NH-based company plans to raise $60 million by offering 4 million shares at a price range of $14 to $16. At the midpoint of the proposed range, Vapotherm would command a fully diluted market value of $254 million.
Vapotherm was founded in 1993 and booked $41 million in sales for the 12 months ended September 30, 2018. It plans to list on the NYSE under the symbol VAPO. BofA Merrill Lynch and William Blair are the joint bookrunners on the deal. It is expected to price during the week of November 12, 2018.
